Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025.

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide.

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

The Indian pharmaceutical market (IPM) grew by 8.4 per cent in the financial year (FY) 2025 on the back of major therapies ...

Viking Therapeutics (VKTX) stock receives a Neutral rating at Goldman Sachs due to intense competition in its targeted ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.